Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 10/2009

Open Access 01-10-2009 | Research Letter

Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT

Authors: S. E. Siegelaar, E. S. Kilpatrick, A. S. Rigby, S. L. Atkin, J. B. L. Hoekstra, J. H. DeVries

Published in: Diabetologia | Issue 10/2009

Login to get access

Excerpt

To the Editor: While it is suggested that, in addition to hyperglycaemia, glucose variability can contribute to the severity and development of diabetic neuropathy [1], it is not related to the development of retinopathy and nephropathy in type 1 diabetes [1, 2]. To determine any additional effect of glucose variability—above that assessed by HbA1c and mean glucose—on peripheral and autonomic diabetic neuropathy, we used the datasets collected during the DCCT (available at www.​gcrc.​med.​umn.​edu/​gcrc/​downloads/​dcct.​html, accessed 23–27 January 2009) [3]. …
Literature
1.
Bragd J, Adamson U, Backlund LB, Lins PE, Moberg E, Oskarsson P (2008) Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type1 diabetes over a decade? Diabetes Metab 34:612–616PubMedCrossRef
2.
Kilpatrick ES, Rigby AS, Atkin SL (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486–1490PubMedCrossRef
3.
The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
4.
The Diabetes Control and Complications Trial Research Group (1988) Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of diabetes control and complications trial (DCCT). Diabetes 37:476–481CrossRef
5.
Kilpatrick ES, Rigby AS, Atkin SL (2008) Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia 51:365–371PubMedCrossRef
6.
Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE (2002) Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the diabetes control and complications trial. Diabetes Care 25:275–278PubMedCrossRef
7.
Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644–655PubMed
8.
Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W (1997) Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care 20:1655–1658PubMedCrossRef
9.
Bril V (1999) NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol 41:8–13PubMedCrossRef
10.
Sima AAF (1992) Structure-function interactions in the therapeutic response of diabetic neuropathy. J Diabetes Complicat 6:64–68PubMedCrossRef
11.
Perkins BA, Bril V (2003) Diabetic neuropathy: a review emphasizing diagnostic methods. Clin Neurophysiol 114:1167–1175PubMedCrossRef
Metadata
Title
Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT
Authors
S. E. Siegelaar
E. S. Kilpatrick
A. S. Rigby
S. L. Atkin
J. B. L. Hoekstra
J. H. DeVries
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1473-x

Other articles of this Issue 10/2009

Diabetologia 10/2009 Go to the issue

Article

Leptin prevents the metabolic effects of adiponectin in L6 myotubes

Short Communication

Retinal vessel calibre and micro- and macrovascular complications in type 1 diabetes

Meta-analysis

Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses

Article

Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study in the Young

Article

Regulation of insulin gene expression by cytokines and cell–cell interactions in mouse medullary thymic epithelial cells

Short Communication

Incidence of insulin-requiring diabetes in the US military
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits